ADAM17 and breast carcinoma: Our results are consistent with previous studies showing that ADAM17 silencing significantly decreased the growth of nasopharyngeal cancer cells [54] as well as cell viability, growth, and proliferation rate of breast cancer cells [55] and suppressed cell viability of esophageal squamous cell carcinoma [56,57].